138 related articles for article (PubMed ID: 31294619)
1. Immunomodulatory effects of topical diphencyprone for the treatment of acute urban cutaneous leishmaniasis.
Nahidi Y; Mashayekhi Goyonlo V; Layegh P; Taghavi F; Najaf Najafi M
J Dermatolog Treat; 2021 Mar; 32(2):220-226. PubMed ID: 31294619
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the efficacy and safety of vascular IPL for treatment of acute cutaneous leishmaniasis: a randomized controlled trial.
Tafazzoli Z; Nahidi Y; Mashayekhi Goyonlo V; Morovatdar N; Layegh P
Lasers Med Sci; 2021 Apr; 36(3):631-640. PubMed ID: 32681219
[TBL] [Abstract][Full Text] [Related]
3. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.
Khatami A; Talaee R; Rahshenas M; Khamesipour A; Mehryan P; Tehrani S; Dowlati Y; Firooz A
PLoS One; 2013; 8(6):e66123. PubMed ID: 23826087
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.
Javadi A; Khamesipour A; Ghoorchi M; Bahrami M; Khatami A; Sharifi I; Eskandari SE; Fekri A; Aflatoonian MR; Firooz A
PLoS Negl Trop Dis; 2022 Jul; 16(7):e0010569. PubMed ID: 35802749
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
Machado PRL; Ribeiro CS; França-Costa J; Dourado MEF; Trinconi CT; Yokoyama-Yasunaka JKU; Malta-Santos H; Borges VM; Carvalho EM; Uliana SRB
Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
[TBL] [Abstract][Full Text] [Related]
6. Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit.
de Oliveira Duque MC; Quintão Silva JJ; Soares PAO; Magalhães RS; Horta APA; Paes LRB; Rosandiski Lyra M; Pimentel MIF; de Fátima Antonio L; de Camargo Ferreira E Vasconcellos É; Saheki MN; de Almeida Marzochi MC; Valete-Rosalino CM; de Oliveira Schubach A
Acta Trop; 2019 May; 193():176-182. PubMed ID: 30851256
[TBL] [Abstract][Full Text] [Related]
7. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
[TBL] [Abstract][Full Text] [Related]
8. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
Faghihi G; Tavakoli-kia R
Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series.
Arboleda M; Barrantes S; Úsuga LY; Robledo SM
Rev Soc Bras Med Trop; 2019 May; 52():e20180211. PubMed ID: 31141044
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
Sadeghian G; Nilfroushzadeh MA; Iraji F
Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
[TBL] [Abstract][Full Text] [Related]
12. Sugar-based colloidal nanocarriers for topical meglumine antimoniate application to cutaneous leishmaniasis treatment: Ex vivo cutaneous retention and in vivo evaluation.
Aragão Horoiwa T; Cortez M; Sauter IP; Migotto A; Bandeira CL; Cerize NNP; de Oliveira AM
Eur J Pharm Sci; 2020 Apr; 147():105295. PubMed ID: 32145429
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A; Amini Harandi A
Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
[TBL] [Abstract][Full Text] [Related]
14. Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
Mendes L; Guerra JO; Costa B; Silva ASD; Guerra MDGB; Ortiz J; Doria SS; Silva GVD; de Jesus DV; Barral-Netto M; Penna G; Carvalho EM; Machado PRL
Int J Infect Dis; 2021 Feb; 103():358-363. PubMed ID: 33253864
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran.
Khamesipour A; Mohammadi A; Jaafari M; Eskandari S; Tasbihi M; Javadi A; Afshari F; Mortazavi H; Firooz A
East Mediterr Health J; 2022 Sep; 28(9):658-663. PubMed ID: 36205204
[TBL] [Abstract][Full Text] [Related]
16. Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis.
Yesilova Y; Surucu HA; Ardic N; Aksoy M; Yesilova A; Oghumu S; Satoskar AR
J Dermatolog Treat; 2016; 27(1):83-7. PubMed ID: 26105204
[TBL] [Abstract][Full Text] [Related]
17. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Munir A; Janjua SA; Hussain I
Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration.
Alkhawajah AM; Larbi E; al-Gindan Y; Abahussein A; Jain S
Ann Trop Med Parasitol; 1997 Dec; 91(8):899-905. PubMed ID: 9579209
[TBL] [Abstract][Full Text] [Related]
20. Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
Aflatoonian MR; Sharifi I; Aflatoonian B; Bamorovat M; Heshmatkhah A; Babaei Z; Ghasemi Nejad Almani P; Mohammadi MA; Salarkia E; Aghaei Afshar A; Sharifi H; Sharifi F; Khosravi A; Khatami M; Arefinia N; Fekri A; Farajzadeh S; Khamesipour A; Mohebali M; Gouya MM; Shirzadi MR; Varma RS
PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007423. PubMed ID: 31188834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]